Cohance Lifesciences Ltd (BOM:543064)

Q2 2026 Cohance Lifesciences Ltd Earnings Call Transcript

Nov 12, 2025 / 01:30 PM GMT

Release Date Price: ₹689.55 (-0.25%)

Transcript

Key Points

Positve

Cohance Lifesciences Ltd (BOM:543064) has established three distinct business verticals, each led by experienced industry leaders, enhancing operational ownership and accountability.
The company received US regulatory approval for a late-stage molecule in the respiratory inflammatory segment, marking a significant milestone for its CDMO platform.
Cohance Lifesciences Ltd (BOM:543064) has strengthened its leadership and technical talent base, adding senior professionals from top global and Indian pharma companies.
The company has a strong pipeline with nine phase 3 molecules, with four expected to transition into commercial supply over the next 12 to 18 months.
Cohance Lifesciences Ltd (BOM:543064) has completed four major customer audits successfully, indicating strong quality and delivery standards.

Negative

The company experienced an 8% year-on-year decline in revenue for the quarter, primarily due to shipment delays at its CDMO and FDF sites.
There were challenges with restocking key molecules and delayed reloads of a few phase 3 molecules, affecting overall performance.
The Nachara plant faced a shutdown awaiting audit clearance, impacting order shipments and production cycles.
The biotech funding environment has been challenging, affecting NJ Bio's project shipments and timelines.
Cohance Lifesciences Ltd (BOM:543064) revised its FY26 guidance to be broadly flat compared to FY25, citing ongoing challenges and destocking issues.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

COHA.NS - Cohance Lifesciences Ltd
Q2 2026 Cohance Lifesciences Ltd Earnings Call
Nov 12, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Q2 and H1F526 earnings conference call of Khans Life Sciences Limited.

As a reminder, all participant clients will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing and then 0 on your touchstone phone.

Please note that this conference is being recorded.

I now hand the conference over to Miss Cinderella Caravello.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.